Andere Kunden interessierten sich auch für
![Breast Cancer is the leading cause of cancer deaths among women]( "Breast Cancer is the leading cause of cancer deaths among women")
Breast Cancer is the leading cause of cancer deaths among women23,99 €![Chow Chow Book]( "Chow Chow Book")
Chow Chow Book30,99 €![Microsponge- A New System for Actinic Keratosis (Pre-Cancer)]( "Microsponge- A New System for Actinic Keratosis (Pre-Cancer)")
Microsponge- A New System for Actinic Keratosis (Pre-Cancer)36,99 €![Ovarian Cancer in Central Sudan]( "Ovarian Cancer in Central Sudan")
Ovarian Cancer in Central Sudan56,99 €![Telomerase and Suicide Cancer Therapy]( "Telomerase and Suicide Cancer Therapy")
Telomerase and Suicide Cancer Therapy39,99 €![Culture and Retardation]( "Culture and Retardation")
Culture and Retardation39,99 €![Culture and Retardation]( "Culture and Retardation")
Culture and Retardation39,99 €
PET/CT has higher sensitivity, specificity and accuracy in detection of metastatic spread and follows up after treatment. The aim of this study: to assess of the impact of PET/CT in patients with MBC and monitoring the therapy response in relation to different molecular sub-types. Material and Methods: 40 patients classified into 4 molecular sub-types; Luminal A like 13 patients, Luminal B+ sub type 15 patients, Luminal B- sub type 4 patients and Basal like sub type 8 patients. All patients performed PET-CT before treatment, while 34 patients perform PET-CT at end of therapy. Results: on lesion based analysis 120 metastatic lesions are seen in CT and bone scan and 76 lesions are seen in PET/CT. During follow up, the majority of luminal A group showed complete response to therapy luminal B+ subgroup showed partial response and most of basal-like subgroup showed progressive disease. Conclusion: PET/CT can detect metastatic spread in breast cancer and monitor therapy response in relation to different molecular sub-types. The mean SUV max showed relation to the different molecular sub-types.